Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateBusiness Wire • 02/26/25
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should KnowZacks Investment Research • 02/26/25
Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)Business Wire • 02/24/25
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025Business Wire • 02/19/25
Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 02/17/25
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's WhyZacks Investment Research • 01/30/25
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/24/25
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 ResultsZacks Investment Research • 01/16/25
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 01/14/25
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate UpdatesBusiness Wire • 01/13/25
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/25
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?Zacks Investment Research • 12/12/24
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver MeetingBusiness Wire • 11/14/24
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 11/12/24
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024Business Wire • 11/04/24
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/31/24